Heung-Chae Jung

Heung-Chae Jung

Auto-generated profile, based on publicly available information

Heung-Chae Jung

Systems Microbiology Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 305-806, Republic of Korea

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 1998 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
HJHeung-Chae Jung
Heung-Chae Jung
JLJean-Michel Lebeault
Jean-Michel Lebeault
JPJae-Gu Pan
Jae-Gu Pan

28 March 2011 in AMB Express
Verified
Journal Article
Open access
PDF file
JKJi-Yeon Kang
Ji-Yeon Kang
SKSo-Young Kim
So-Young Kim
DKDooil Kim
Dooil Kim
Dong Hyun KimDong Hyun Kim
Dong Hyun Kim
SSSun-Mi Shin
Sun-Mi Shin
CYChul-Ho Yun
Chul-Ho Yun
An extreme diversity of substrates and catalytic reactions of cytochrome P450 (P450) enzymes is considered to be the consequence of evolutionary adaptation driven by different metabolic or environmental demands. Here we report the presence of numerous natural variants of P450 BM3 (CYP102A1) within a species of Bacillus megaterium. Extensive amino acid substitutions (up to 5% of the total 1049 amino acid residues) were identified from the variants. Phylogenetic analyses suggest that this P450 gene evolve more rapidly than the rRNA gene locus. It was found that key catalytic residues in the substrate channel and active site are retained. Although there were no apparent variations in hydroxylation activity towards myristic acid (C14) and palmitic acid (C16), the hydroxylation rates of lauric acid (C12) by the variants varied in the range of >25-fold. Interestingly, catalytic activities of the variants are promiscuous towards non-natural substrates including human P450 substrates. It can be suggested that CYP102A1 variants can acquire new catalytic activities through site-specific mutations distal to the active site.

1 February 2000 in Applied and Environmental Microbiology
Verified
Journal Article
Closed access
PDF file
Yong-Sung KimYong-Sung Kim
Yong-Sung Kim
HJHeung-Chae Jung
Heung-Chae Jung
JPJae-Gu Pan
Jae-Gu Pan
The bacterial surface display method was used to selectively screen for improved variants of carboxymethyl cellulase (CMCase). A library of mutated CMCase genes generated by DNA shuffling was fused to the ice nucleation protein (Inp) gene so that the resulting fusion proteins would be displayed on the bacterial cell surface. Some cells displaying mutant proteins grew more rapidly on carboxymethyl cellulose plates than controls, forming heterogeneous colonies. In contrast, cells displaying the nonmutated parent CMCase formed uniform tiny colonies. These variations in growth rate were assumed to result from altered availability of glucose caused by differences in the activity of variant CMCases at the cell surface. Staining assays indicate that large, rapidly growing colonies have increased CMCase activity. Increased CMCase activity was confirmed by assaying the specific activities of cell extracts after the expression of unfused forms of the variant genes in the cytoplasm. The best-evolved CMCases showed about a 5- and 2.2-fold increase in activity in the fused and free forms, respectively. Sequencing of nine evolved CMCase variant genes showed that most amino acid substitutions occurred within the catalytic domain of the enzyme. These results demonstrate that the bacterial surface display of enzyme libraries provides a direct way to correlate evolved enzyme activity with cell growth rates. This technique will provide a useful technology platform for directed evolution and high-throughput screening of industrial enzymes, including hydrolases.

1 July 2007 in Trends in Biotechnology
Verified
Journal Article
Closed access
CYChul-Ho Yun
Chul-Ho Yun
KKKeon-Hee Kim
Keon-Hee Kim
DKDong-Hyun Kim
Dong-Hyun Kim
HJHeung-Chae Jung
Heung-Chae Jung
JPJae-Gu Pan
Jae-Gu Pan

1 April 1998 in Enzyme and Microbial Technology
Verified
Journal Article
Closed access
HJHeung-Chae Jung
Heung-Chae Jung
JPJoon-Hyun Park
Joon-Hyun Park
SPSeung-Hwan Park
Seung-Hwan Park
JLJean-Michel Lebeault
Jean-Michel Lebeault
JPJae-Gu Pan
Jae-Gu Pan

1 May 2009 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
PDF file
DKDong-Hyun Kim
Dong-Hyun Kim
TATaeho Ahn
Taeho Ahn
HJHeung-Chae Jung
Heung-Chae Jung
JPJae-Gu Pan
Jae-Gu Pan
CYChul-Ho Yun
Chul-Ho Yun
In recent studies, the wild-type and mutant forms of cytochrome P450 (P450) BM3 (CYP102A1) from Bacillus megaterium were found to metabolize various drugs through reactions similar to those catalyzed by human P450 enzymes. Therefore, it was suggested that CYP102A1 can be used to produce large quantities of the metabolites of human P450-catalyzed reactions. trans-Resveratrol (3,4′,5-trihydroxystilbene), an anticancer-preventive agent, is oxidized by human P450 1A2 to produce two major metabolites, piceatannol (3,5,3′,4′-tetrahydroxystilbene) and another hydroxylated product. In this report, we show that the oxidation of trans-resveratrol, a human P450 1A2 substrate, is catalyzed by wild-type and a set of CYP102A1 mutants. One major hydroxylated product, piceatannol, was produced as a result of the hydroxylation reaction. Other hydroxylated products were not produced. Piceatannol formation was confirmed by high-performance liquid chromatography and gas chromatograph-mass spectrometry by comparing the metabolite with the authentic piceatannol compound. These results demonstrate that CYP102A1 mutants can be used to produce piceatannol, a human metabolite of resveratrol.